[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652421":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":40,"centralContacts":40,"locations":41,"responsibleParty":216,"collaborators":40,"id":218,"slug":219,"hasResults":220,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":40,"eligibilityCriteria":224,"healthyVolunteers":220,"sex":225,"minAge":226,"maxAge":40,"enrollmentInfo":227,"targetDuration":40,"studyType":230,"phases":231,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":241,"whyStopped":40,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":251},{"fullName":5,"class":6},"VelaVigo Bio Inc","INDUSTRY",[8,14,18,22,26,30],{"label":9,"type":10,"description":11,"interventionNames":12},"VBC117 Dose Level 1","EXPERIMENTAL","Phase 1 dose escalation and backfill: VBC117 at Dose Level 1",[13],"Drug: VBC117",{"label":15,"type":10,"description":16,"interventionNames":17},"VBC117 Dose Level 2","Phase 1 dose escalation and backfill: VBC117 at Dose Level 2",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"VBC117 Dose Level 3","Phase 1 dose escalation and backfill: VBC117 at Dose Level 3",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"VBC117 Dose Level 4","Phase 1 dose escalation and backfill: VBC117 at Dose Level 4",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"VBC117 Dose Level 5","Phase 1 dose escalation and backfill: VBC117 at Dose Level 5",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"VBC117 Dose Level RP2D","Phase 2a expansion cohort: VBC117 at RP2D across tumor-specific cohorts",[13],[35],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"DRUG","VBC117","VBC117 is a epidermal growth factor receptor (EGFR)x Cadherin-17 (CDH17) bispecific antibody-drug conjugate (ADC).",[9,15,19,23,27,31],null,[42,61,71,85,100,117,132,147,166,176,191,201],{"facility":43,"status":40,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Macquarie University","Randwick","New South Wales","2031","Australia","AU",{"type":50,"coordinates":51},"Point",[52,53],151.24895,-33.91439,{"lat":53,"lon":52},[56],{"name":57,"role":58,"phone":59,"phoneExt":40,"email":60},"Andrew Parsonson","CONTACT","+61 2 9812 3538","andrew.parsonson@mqhealth.org.au",{"facility":62,"status":40,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"Scientia Clinical Research",{"type":50,"coordinates":64},[52,53],{"lat":53,"lon":52},[67],{"name":68,"role":58,"phone":69,"phoneExt":40,"email":70},"Charlotte Lemech","+61 2 9382 5807","charlotte.lemech@scientiaclinicalresearch.com.au",{"facility":72,"status":40,"city":73,"state":45,"zip":74,"country":47,"countryCode":48,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Cancer Care Wollongong","Wollongong","2500",{"type":50,"coordinates":76},[77,78],150.89345,-34.424,{"lat":78,"lon":77},[81],{"name":82,"role":58,"phone":83,"phoneExt":40,"email":84},"Udit Nindra","+61 0437 000 874","udit.nindra@health.nsw.gov.au",{"facility":86,"status":40,"city":87,"state":88,"zip":89,"country":47,"countryCode":48,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Peninsula and South Eastern Haematology and Oncology Group","Frankston","Victoria","3199",{"type":50,"coordinates":91},[92,93],145.12291,-38.14458,{"lat":93,"lon":92},[96],{"name":97,"role":58,"phone":98,"phoneExt":40,"email":99},"Vinod Ganju","+61 03 9113 1301","vg@paso.com.au",{"facility":101,"status":40,"city":102,"state":103,"zip":104,"country":105,"countryCode":106,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"The Second Affiliated Hospital of Zhejiang University School of Medicine","Zhejiang","Hangzhou","310009","China","CN",{"type":50,"coordinates":108},[109,110],105.583,25.3238,{"lat":110,"lon":109},[113],{"name":114,"role":58,"phone":115,"phoneExt":40,"email":116},"Shanshan Weng","+86 13558118823","Nicolweng1986010@163.com",{"facility":118,"status":40,"city":119,"state":120,"zip":121,"country":105,"countryCode":106,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","450052",{"type":50,"coordinates":123},[124,125],113.64861,34.75778,{"lat":125,"lon":124},[128],{"name":129,"role":58,"phone":130,"phoneExt":40,"email":131},"Shuiling Jin","+86 13838008938","13838008938@163.com",{"facility":133,"status":40,"city":134,"state":135,"zip":136,"country":105,"countryCode":106,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Hunan Cancer Hospital","Changsha","Hunan","410013",{"type":50,"coordinates":138},[139,140],112.97087,28.19874,{"lat":140,"lon":139},[143],{"name":144,"role":58,"phone":145,"phoneExt":40,"email":146},"Zhenyang Liu","+86 18673181133","liuzhenyang@hnca.org.cn",{"facility":148,"status":40,"city":149,"state":150,"zip":151,"country":105,"countryCode":106,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"The Second Affiliated Hospital of Nanchang University","Nanchang","Jiangxi","330006",{"type":50,"coordinates":153},[154,155],115.85306,28.68396,{"lat":155,"lon":154},[158,162],{"name":159,"role":58,"phone":160,"phoneExt":40,"email":161},"Hua Wang","+86 13667098735","dcWanghua@126.com",{"name":163,"role":58,"phone":164,"phoneExt":40,"email":165},"Jian Li","+86 13979107989","efyjgb@126.com",{"facility":167,"status":40,"city":168,"state":169,"zip":170,"country":105,"countryCode":106,"cosmosGeoPoint":40,"geoPoint":40,"contacts":171},"Liaoning Cancer Hospital & Institute","Shengyang","Liaoning","110042",[172],{"name":173,"role":58,"phone":174,"phoneExt":40,"email":175},"Jinghui Bai","+86 18900917098","18900917098@163.com",{"facility":177,"status":40,"city":178,"state":179,"zip":180,"country":105,"countryCode":106,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Shanghai East Hospital","Shanghai","Shanghai Municipality","200120",{"type":50,"coordinates":182},[183,184],121.45806,31.22222,{"lat":184,"lon":183},[187],{"name":188,"role":58,"phone":189,"phoneExt":40,"email":190},"Ye Guo","+86 13501678472","pattrickguo@gmail.com",{"facility":192,"status":40,"city":178,"state":179,"zip":180,"country":105,"countryCode":106,"cosmosGeoPoint":193,"geoPoint":195,"contacts":196},"Shanghai GoBroad Cancer Hospital",{"type":50,"coordinates":194},[183,184],{"lat":184,"lon":183},[197],{"name":198,"role":58,"phone":199,"phoneExt":40,"email":200},"Jin Li","+86 13761222111","lijin@csco.org.cn",{"facility":202,"status":40,"city":203,"state":204,"zip":205,"country":105,"countryCode":106,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"First Hospital of Shanxi Medical University","Taiyuan","Shanxi","030001",{"type":50,"coordinates":207},[208,209],112.56028,37.86944,{"lat":209,"lon":208},[212],{"name":213,"role":58,"phone":214,"phoneExt":40,"email":215},"Yusheng Wang","+86 13834646436","wangyusheng1972@163.com",{"type":217,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100652421","phase-1-vbc117first-in-human-trial-of-vbc117-in-participants-with-advanced-malignant-solid-tumors-100652421",false,"NCT07772934","VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors","Phase 1\u002F2a Open-label Clinical Trial Evaluating VBC117, an EGFR and CDH17-directed Bi-specific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n1. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure.\n2. Histologically or cytologically confirmed unresectable advanced\u002Fmetastatic solid tumor .\n3. At least one measurable lesion as assessed by the investigator according to RECIST v1.1 criteria.\n4. Male or female adults (defined as ≥ 18 years of age).\n5. ECOG performance status 0-1.\n6. Life expectancy greater than 12 weeks.\n7. Archived tumor tissue sample available or able to undergo a fresh biopsy collection.\n8. Adequate organ and bone marrow function.\n\nExclusion Criteria:\n\n1. Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment.\n2. Known or suspected brain metastases, or spinal cord compression.\n3. Prior treatment with an ADC targeting EGFR x CDH17 bispecific ADC.\n4. Prior treatment with any ADC carrying a topoisomerase I inhibitor (TOP1i) payload.\n5. Has a medical history of interstitial lung diseases or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.","ALL","18 Years",{"count":228,"type":229},260,"ESTIMATED","INTERVENTIONAL",[232,233],"PHASE1","PHASE2","Detailed Description: This is a multicenter, open-label, multiple-dose, first in human(FIH) Phase 1\u002F2a trial. The Phase 1 portion uses the Bayesian optimal interval (BOIN) design to escalate doses and determine the maximum tolerated dose(MTD) and\u002For recommended phase 2 dose(RP2D) with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies treated with VBC117.",[236],"Advanced Solid Tumors",[236,37,238,239,240],"Phase 1","Phase 2a","Dose Escalation","NOT_YET_RECRUITING","2026-08-14",{"date":244,"type":245},"2026-08-19","ACTUAL",{"date":247,"type":229},"2026-08-24",{"date":249,"type":229},"2029-05-28",{"name":5,"class":6},12]